BIOYONG established in 2011. It is the first enterprise focusing on the research and development of clinical mass spectrometry. The time-of-flight mass spectrometry (Clin-TOF) produced by Bioyong received the medical device certification from National Medical Products Administration (NMPA) in June 2016. As the first clinical mass spectrometry enterprise in China to obtained a NMPA certification, BIOYONG pioneered and realized the single-machine multi-omics detection. One machine can meet the clinical applications in the fields of microbial identification and nucleic acid detection, and its technology has fully reached the international leading level. Also the Clin-ICP-QMS-I produced by Bioyong received the NMPA certification in 2019. Up to now, well-konwn investment companies such as Softbank Saifu, Chongde Hongxin(Beijing), and Hanfu Capital have
invested more than 100 million yuan in BIOYONG.